98%
921
2 minutes
20
Transient receptor potential vanilloid 4 (TRPV4) is a ubiquitously expressed polymodally activated ion channel. TRPV4 has been implicated in tumor progression; however, the cell-specific role of TRPV4 in tumor growth, angiogenesis, and metastasis is unknown. Here, we generated endothelial-specific TRPV4 knockout (TRPV4) mice by crossing TRPV4 mice with Tie2-Cre mice. Tumor growth and metastasis were significantly increased in a syngeneic Lewis lung carcinoma tumor model of TRPV4 mice compared to TRPV4 mice. Multiphoton microscopy, dextran leakage, and immunohistochemical analysis revealed increased tumor angiogenesis and metastasis that were correlated with aberrant leaky vessels (increased width and reduced pericyte and VE-cadherin coverage). Mechanistically, increases in VEGFR2, p-ERK, and MMP-9 expression and DQ gelatinase activity were observed in the TRPV4 mouse tumors. Our results demonstrated that endothelial TRPV4 is a critical modulator of vascular integrity and tumor angiogenesis and that deletion of TRPV4 promotes tumor angiogenesis, growth, and metastasis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8295186 | PMC |
http://dx.doi.org/10.1007/s10456-021-09775-9 | DOI Listing |
Chin Med J (Engl)
September 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xi'an, Shaanxi 710032, China.
The success of chimeric antigen receptor T (CAR-T) cells therapy for hematologic malignancies has sparked interest in potential applications for solid tumors. However, unlike the homogeneous, dynamic, and nutrient-rich hematologic environment, CAR-T cells must overcome the complex tumor microenvironment. Ensuring efficient contact with tumor cells remains a primary challenge to enhance the efficacy of CAR-T cell therapy.
View Article and Find Full Text PDFCell Rep Med
August 2025
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:
Despite the clinical use of anti-vascular endothelial growth factor (VEGF) antibodies (AVAs) in cancer therapy, resistance frequently develops, leading to disease progression. To address this, we identify a previously unknown role for breast cancer type 1 susceptibility protein (BRCA1)-associated RING domain 1 (BARD1) in modulating AVA sensitivity. Epigenetic modulation-via global and targeted DNA methylation-reveals BARD1 as a key regulator of angiogenesis.
View Article and Find Full Text PDFBiology (Basel)
July 2025
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.
Natural products, characterized by their structural novelty, multi-target capabilities, and favorable toxicity profiles, represent a prominent reservoir for the discovery of innovative anticancer therapeutics. In the current investigation, we identified ajuforrestin A, a diterpenoid compound extracted from Maxim, as a potent agent against lung cancer. In vitro, this compound markedly curtailed the proliferation of A549 cells.
View Article and Find Full Text PDFDiscov Oncol
September 2025
Department of Plastic Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Objective: This research seeks to comprehensively explore the expression patterns of Angiopoietin-2 (ANGPT2) in pan-cancer and examine its relationship with clinical outcomes, tumor immune microenvironment dynamics, and biological functions, with particular emphasis on skin cutaneous melanoma (SKCM).
Methods: Data from six databases, including UCSC Xena, TCGA, GTEx, TIMER2.0, GEPIA, and cBioPortal, were analyzed to assess ANGPT2 expression in pan-cancer.
Signal Transduct Target Ther
August 2025
Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.